Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.5434
+0.0144 (2.72%)
At close: Nov 17, 2026, 4:00 PM EST
0.5480
+0.0046 (0.85%)
After-hours: Nov 17, 2026, 5:13 PM EST
Company Description
Valion Bio, Inc. operates as a late-stage biopharmaceutical company.
Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence.
In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026.
The company was incorporated in 2016 and is based in San Antonio, Texas.
Valion Bio, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Nov 11, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | J. Zikria |
Contact Details
Address: 1305 E. Houston Street, Suite 311, Building 1 San Antonio, Texas 78205 United States | |
| Phone | 888 276 6888 |
| Website | valionbio.com |
Stock Details
| Ticker Symbol | VBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1787740 |
| CUSIP Number | 918942202 |
| ISIN Number | US9189422028 |
| Employer ID | 81-4016391 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| J. Dean Zikria | Interim Chief Executive Officer and Director |
| Lisa G. Wolf | President, Chief Financial Officer and Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 16, 2026 | 8-K | Current Report |
| Nov 16, 2026 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 12, 2026 | SCHEDULE 13G/A | Filing |
| Nov 9, 2026 | 8-K | Current Report |
| Nov 5, 2026 | 8-K | Current Report |
| Nov 2, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 27, 2026 | 8-K | Current Report |
| Oct 26, 2026 | 8-K | Current Report |
| Oct 22, 2026 | 8-K | Current Report |